Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) has been given a $58.00 price objective by equities research analysts at Jefferies Group in a report released on Thursday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Jefferies Group’s price target would suggest a potential upside of 21.14% from the stock’s current price.
Several other research firms have also recently issued reports on ALNY. Cowen and Company reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, November 3rd. Needham & Company LLC cut shares of Alnylam Pharmaceuticals to a “buy” rating and decreased their price objective for the company from $152.00 to $137.00 in a report on Thursday, October 6th. Barclays PLC reiterated a “hold” rating and issued a $50.00 price objective on shares of Alnylam Pharmaceuticals in a report on Thursday, November 3rd. Janney Montgomery Scott began coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 28th. They issued a “neutral” rating and a $74.00 price objective for the company. Finally, Leerink Swann reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Monday, September 26th. Eight research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $68.63.
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded up 0.40% during mid-day trading on Thursday, reaching $47.88. 524,185 shares of the company’s stock traded hands. Alnylam Pharmaceuticals has a 52-week low of $31.38 and a 52-week high of $109.10. The company’s market capitalization is $4.11 billion. The company has a 50-day moving average of $39.69 and a 200-day moving average of $59.81.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Wednesday, November 2nd. The biopharmaceutical company reported ($1.21) EPS for the quarter, missing the consensus estimate of ($1.14) by $0.07. Alnylam Pharmaceuticals had a negative return on equity of 33.97% and a negative net margin of 1,041.16%. The firm earned $13.70 million during the quarter, compared to the consensus estimate of $9.14 million. During the same quarter last year, the company posted ($0.91) EPS. Alnylam Pharmaceuticals’s revenue for the quarter was up 116.7% on a year-over-year basis. Equities research analysts expect that Alnylam Pharmaceuticals will post ($4.81) EPS for the current year.
In related news, Director David E. I. Pyott bought 27,900 shares of the business’s stock in a transaction on Thursday, October 13th. The stock was bought at an average price of $37.00 per share, for a total transaction of $1,032,300.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 4.00% of the stock is currently owned by company insiders.
Large investors have recently added to or reduced their stakes in the company. Dodge & Cox bought a new stake in Alnylam Pharmaceuticals during the second quarter worth about $139,650,000. Deerfield Management Co. bought a new stake in Alnylam Pharmaceuticals during the second quarter worth about $18,645,000. Janus Capital Management LLC increased its stake in Alnylam Pharmaceuticals by 908.8% in the second quarter. Janus Capital Management LLC now owns 358,122 shares of the biopharmaceutical company’s stock worth $19,871,000 after buying an additional 322,622 shares during the last quarter. Westfield Capital Management Co. LP bought a new stake in Alnylam Pharmaceuticals during the second quarter worth about $15,358,000. Finally, State Street Corp increased its stake in Alnylam Pharmaceuticals by 13.4% in the second quarter. State Street Corp now owns 2,195,504 shares of the biopharmaceutical company’s stock worth $121,832,000 after buying an additional 258,984 shares during the last quarter. Institutional investors own 85.24% of the company’s stock.
About Alnylam Pharmaceuticals